secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAVEX LIFE SCIENCES CORP. (AVXL)
CIK:        0001314052
Form:       8-K
Filed at:   2026-07-30T12:15:52+00:00
Accession:  0001731122-26-000988
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anavex reports preliminary Q2 FY2026 net loss of $5.3M; cash $127.4M; focuses on FDA for Alzheimer's
--------------------------------------------------------------------------------

- Preliminary net loss $5.3M ($0.06/share) vs $11.2M ($0.13/share) in Q2 2025; R&D expenses down to $4.2M from $9.9M.
- Cash and equivalents $127.4M as of March 31, 2026, up from $102.6M at Sept 30, 2025; expected to fund operations into mid-to-late FY2028.
- Opened IND for early Alzheimer's disease with FDA in March 2026; ADME study expected Q3 2026, DDI study underway.
- Aligned with FDA on Phase 3 Rett syndrome protocol for adults; plans to discuss adding pediatric patients.
- Submitted plan to regain Nasdaq compliance on July 20, 2026 (Listing Rule 5250(c)(1)).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314052/000173112226000988/0001731122-26-000988-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314052/000173112226000988/e7813_8-k.htm
  HTML page:      https://secwatch.observer/filing/0001731122-26-000988

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer